Comparing two treatments for insomnia in veterans with PTSD

A Novel Acceptance-based Treatment for Insomnia in Veterans With Post-Traumatic Stress Disorder

NA · VA Office of Research and Development · NCT05194930

This study is trying out a new treatment for insomnia that combines different therapy techniques to see if it helps veterans with PTSD sleep better and feel less anxious compared to standard therapy.

Quick facts

PhaseNA
Study typeInterventional
Enrollment400 (estimated)
Ages18 Years and up
SexAll
SponsorVA Office of Research and Development (fed)
Locations1 site (Sepulveda, California)
Trial IDNCT05194930 on ClinicalTrials.gov

What this trial studies

This randomized trial evaluates the effectiveness of a novel treatment called Acceptance of the Behavioral Changes to Treat Insomnia (ABC-I) against the standard Cognitive Behavioral Therapy for Insomnia (CBT-I) in veterans suffering from both insomnia and Post-Traumatic Stress Disorder (PTSD). ABC-I integrates behavioral components from CBT-I with elements of Acceptance and Commitment Therapy to enhance treatment adherence. The study aims to assess the impact of ABC-I on reducing PTSD symptoms and improving sleep quality compared to CBT-I. Veterans receiving care at Sepulveda and West Los Angeles facilities will be recruited for participation.

Who should consider this trial

Good fit: Ideal candidates are community-dwelling veterans aged 18 and older who have received care from the VA Greater Los Angeles Healthcare System and live within a 50-mile radius.

Not a fit: Patients who are currently pregnant, have severe untreated sleep disorders, or unstable medical or psychiatric conditions may not benefit from this study.

Why it matters

Potential benefit: If successful, this study could provide a more effective treatment option for veterans struggling with insomnia and PTSD.

How similar studies have performed: While there is evidence supporting CBT-I for insomnia in individuals with psychiatric comorbidities, this specific comparison of ABC-I to CBT-I is novel and has not been extensively tested.

Eligibility criteria

Show full inclusion / exclusion criteria
Inclusion Criteria:

* community-dwelling Veterans aged 18 years and older,
* received care from VAGLAHS in the prior year,
* live within a 50-mile radius of the research offices at the VA Sepulveda Ambulatory Care Center,
* have symptoms of PTSD,
* have symptoms of insomnia.

Exclusion Criteria:

* current pregnancy or has a child less than 6 months of age (men and women),
* active substance users or in recovery with less than 90 days of sobriety,
* too ill to engage in the study procedures,
* unable to self-consent to participate,
* unstable housing (since we may not be able to retrieve costly and difficult to replace monitoring equipment),
* severe, untreated sleep disordered breathing (AHI\>15 with excessive daytime sleepiness, or AHI\>30),
* restless legs syndrome that accounts for the sleep disturbances reported,
* a circadian rhythm sleep disorder that accounts for the sleep disturbances reported (including shift work sleep disorder),
* unstable medical or psychiatric disorders (which is a contraindication for behavioral treatment of insomnia);
* remission of insomnia symptoms prior to randomization;
* current participation in prolonged exposure therapy for PTSD.

Where this trial is running

Sepulveda, California

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.

View on ClinicalTrials.gov →

Conditions: Insomnia, PTSD, Insomnia disorder, Chronic Post-Traumatic Stress Disorder

Last reviewed 2026-05-15 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.